Emma Hitt, PhD


Neoadjuvant chemo is well tolerated in high-risk PCa

September 01, 2006

Atlanta-Neoadjuvant docetaxel added to androgen suppression therapy and radiation therapy appears to be safe and active in patients with high-risk localized prostate cancer, according to findings of a new phase II study from Canada reported here at the American Society of Clinical Oncology annual meeting.

RALP may offer improved margins, ease of transition

September 01, 2006

Atlanta-Positive surgical margin rates decrease as experience with robot-assisted laparoscopic prostatectomy (RALP) increases. In addition, formal laparoscopic training may not be necessary for optimizing some outcomes with the robotic procedure, according to the findings of two new studies presented here at the AUA annual meeting.

Smaller prostate gland associated with high-grade PCa

September 01, 2006

Atlanta-Men with smaller prostate glands appear to be more likely to develop prostate cancer and have higher Gleason sum disease than are men with larger prostates, according to the results of a new prospective analysis.

RRP vs. XRT: Similar outcomes, some quality of life differences

September 01, 2006

Surgery has greater impact on urinary function;......radiation therapy, on bowel function